文献速递心脑血管急症重症综合管理与镇静镇痛

急性脑损伤后脑电图痫样异常与癫痫发生的关联

Association of Epileptiform Abnormality on Electroencephalography with Development of Epilepsy After Acute Brain Injury.
PubMed 文献 · Neurocrit Care · 2021-01-20
一句话结论急性脑损伤患者cEEG出现痫样异常与远期新发癫痫风险增加逾3倍相关,可作为风险分层工具。

31例(30.7%)cEEG存在痫样异常(LPDs、LRDA、GPDs、sIEDs)。中位随访19.1个月,25.7%患者新发癫痫;痫样异常组癫痫发生率高于无痫样异常组(41.9% vs 18.6%,p=0.025)。多变量Cox回归校正后,痫样异常与新发癫痫风险显著增加相关(HR 3.39;95%CI 1.39-8.26;p=0.007)。

要点

  • 急性脑损伤患者cEEG出现痫样异常(LPDs、LRDA、GPDs、sIEDs)者远期新发癫痫风险为无痫样异常者的3.39倍(95%CI 1.39-8.26)。
  • 痫样异常组癫痫发生率为41.9%,无痫样异常组为18.6%(p=0.025)。
  • 痫样异常组随访期间继续使用抗癫痫药物比例更高(67.7% vs 38.6%,p=0.009)。
  • cEEG中位监测时间在入院后2天(IQR 1-5天),至少监测6小时。
  • cEEG痫样异常可作为急性脑损伤后长期癫痫风险分层的生物标志物。

适用人群与场景

  • 急性脑损伤患者,包括缺血性或出血性卒中、创伤性脑损伤、脑炎或后部可逆性脑病综合征。
  • 纳入标准:指数住院期间cEEG监测至少6小时,且随访至少12个月。
  • 排除人群:原文未提及。

诊断标准与关键阈值

  • 痫样异常定义:cEEG出现偏侧周期性放电(LPDs)、偏侧节律性δ活动(LRDA)、全面性周期性放电(GPDs)或散发性发作间期痫样放电(sIEDs)。
  • 新发癫痫定义:出院后出现自发性临床癫痫发作。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 中位随访19.1个月(IQR 16.2-24.3),25.7%患者新发癫痫。
  • 痫样异常组癫痫发生率41.9%,无痫样异常组18.6%(p=0.025)。
  • 多变量Cox回归校正年龄、精神状态、cEEG电graphic发作、性别、急性脑损伤病因和出院时抗癫痫药物治疗后,痫样异常与新发癫痫风险独立相关(HR 3.39;95%CI 1.39-8.26;p=0.007)。
  • 痫样异常组随访期间继续使用抗癫痫药物比例更高(67.7% vs 38.6%,p=0.009)。

证据类型、等级与局限

  • 证据类型:回顾性单中心队列研究。

对床旁实践的改变

  • 对急性脑损伤患者,cEEG出现痫样异常提示远期新发癫痫风险显著增加,可据此加强随访和风险告知。
  • 痫样异常组更多患者持续使用抗癫痫药物,提示cEEG结果可能影响出院后抗癫痫治疗决策。
  • 需注意本研究为回顾性观察性研究,不能证明cEEG指导的治疗可改善预后。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVES: Epileptiform abnormalities (EA) on continuous electroencephalography (cEEG) are associated with increased risk of acute seizures; however, data on their association with development of long-term epilepsy are limited. We aimed to investigate the association of EA in patients with acute brain injury (ABI): ischemic or hemorrhagic stroke, traumatic brain injury, encephalitis, or posterior reversible encephalopathy syndrome, and subsequent development of epilepsy.

METHODS: This was a retrospective, single-center study of patients with ABI who had at least 6 hours of cEEG during the index admission between 1/1/2017 and 12/31/2018 and at least 12 months of follow-up. We compared patients with EAs; defined as lateralized periodic discharges (LPDs), lateralized rhythmic delta activity (LRDA), generalized periodic discharges (GPDs), and sporadic interictal epileptiform discharges (sIEDs) to patients without EAs on cEEG. The primary outcome was the new development of epilepsy, defined as the occurrence of spontaneous clinical seizures following hospital discharge. Secondary outcomes included time to development of epilepsy and use of anti-seizure medications (ASMs) at the time of last follow-up visit.

RESULTS: One hundred and one patients with ABI met study inclusion criteria. Thirty-one patients (30.7%) had EAs on cEEG. The median (IQR) time to cEEG was 2 (1-5) days. During a median (IQR) follow-up period of 19.1 (16.2-24.3) months, 25.7% of patients developed epilepsy; the percentage of patients who developed epilepsy was higher in those with EAs compared to those without EAs (41.9% vs. 18.6%, p = 0.025). Patients with EAs were more likely to be continued on ASMs during follow-up compared to patients without EAs (67.7% vs. 38.6%, p = 0.009). Using multivariable Cox regression analysis, after adjusting for age, mental status, electrographic seizures on cEEG, sex, ABI etiology, and ASM treatment on discharge, patients with EAs had a significantly increased risk of developing epilepsy compared to patients without EA (hazard ratio 3.39; 95% CI 1.39-8.26; p = 0.007).

CONCLUSIONS: EAs on cEEG in patients with ABI are associated with a greater than three-fold increased risk of new-onset epilepsy. cEEG findings in ABI may therefore be a useful risk stratification tool for assessing long-term risk of seizures and serve as a biomarker for new-onset epilepsy.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Chen DF, Kumari P, Haider HA, et al. Association of Epileptiform Abnormality on Electroencephalography with Development of Epilepsy After Acute Brain Injury. Neurocrit Care. 2021. PMID: 33469863. doi:10.1007/s12028-020-01182-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。